THOUSAND OAKS, Calif., Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-dosing option for the monthly administration ...

If approved by the European Commission (EC), Repatha would be the first PCSK9 inhibitor in Europe with the option of a single monthly injection. Repatha was the first PCSK9 inhibitor to gain marketing ...

The FINANCIAL — Amgen on July 11 announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system (on-body infusor with prefilled cartridge), a new, ...

Repatha works by blocking a specific enzyme in your liver to help your body remove cholesterol more effectively. It is not an immunosuppressant drug, so it doesn’t work by suppressing the immune ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

How Does Repatha Work for High Cholesterol? People can have high cholesterol for a number of reasons, including their diet, exercise habits, or genetic conditions. Keeping your cholesterol low, ...

Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...

THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication ...

Repatha is an effective medication that can lower LDL cholesterol and significantly reduce the risk of heart attacks and strokes. Like most drugs, Repatha can cause side effects. However long-term ...

Repatha reduced the risk of heart attack by 27%, the risk of stroke by 21% and the risk of coronary revascularization by 22%. Amgen announced that the Food and Drug Administration (FDA) has approved ...

Amgen Inc.AMGN announced that the FDA has approved a new, monthly single-dose administration option for its PCSK9 inhibitor, Repatha. The Repatha Pushtronex system, an on-body infusor with a prefilled ...

Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...